CO7141408A2 - Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis - Google Patents

Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis

Info

Publication number
CO7141408A2
CO7141408A2 CO14200440A CO14200440A CO7141408A2 CO 7141408 A2 CO7141408 A2 CO 7141408A2 CO 14200440 A CO14200440 A CO 14200440A CO 14200440 A CO14200440 A CO 14200440A CO 7141408 A2 CO7141408 A2 CO 7141408A2
Authority
CO
Colombia
Prior art keywords
enuresis
treatment
pharmaceutical composition
urinary incontinence
weight
Prior art date
Application number
CO14200440A
Other languages
English (en)
Inventor
Agusti Juan Carlos Llobregat
Original Assignee
Laboratec S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratec S L filed Critical Laboratec S L
Publication of CO7141408A2 publication Critical patent/CO7141408A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736Prunus, e.g. plum, cherry, peach, apricot or almond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición farmaceutica para tratamiento de incontinencia urinaria y/o enuresis que comprende al menos una mezcla de flavonoides entre el 0,5% - 20 % en peso, de taninos condensados o proantocianidinas entre el 2% - 20% en peso y de ácido Gamma-aminobutírico (GABA) entre el 0,3% - 60% enj peso, sobre el total de la composición. Dicha composición adicionalmente comprende al menos 0% de un extracto de HUmulus lupulus. La presente invención también se refiere al uso de dicha composición para la obtención de un medicamento para tratar la incontinencia y/o enuresis, particularmente la enuresis en niños, así como en adultos o ancianos que tienen perdidas de orina como la incontinencia de estrés o de urgencia.
CO14200440A 2012-02-15 2014-09-10 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis CO7141408A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230242A ES2423254B1 (es) 2012-02-15 2012-02-15 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis

Publications (1)

Publication Number Publication Date
CO7141408A2 true CO7141408A2 (es) 2014-12-12

Family

ID=48983578

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14200440A CO7141408A2 (es) 2012-02-15 2014-09-10 Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis

Country Status (20)

Country Link
US (1) US9272011B2 (es)
EP (1) EP2815755A4 (es)
JP (1) JP6203761B2 (es)
KR (1) KR20140127874A (es)
CN (1) CN104254338B (es)
AU (1) AU2013220284A1 (es)
BR (1) BR112014020154A8 (es)
CA (1) CA2864426A1 (es)
CL (1) CL2014002128A1 (es)
CO (1) CO7141408A2 (es)
CR (1) CR20140419A (es)
EA (1) EA028184B1 (es)
ES (1) ES2423254B1 (es)
IL (1) IL233978A0 (es)
MA (1) MA37324A1 (es)
MX (1) MX367671B (es)
PE (1) PE20142324A1 (es)
PH (1) PH12014501823A1 (es)
WO (1) WO2013121061A1 (es)
ZA (1) ZA201406668B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339316B (zh) * 2019-08-09 2021-09-21 河南中医药大学 一种治疗中风后尿失禁的中药
CN116036153B (zh) * 2023-02-22 2023-09-26 深圳市儿童医院 啤酒花提取物在制备用于治疗或者预防抑郁症、抑郁症并发症、焦虑症的产品中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
SG48288A1 (en) 1992-05-20 1998-04-17 Univ Northwestern Gaba and l-glutamic acid analogs for antiseizure treatment
CA2362026A1 (en) * 1999-04-08 2000-10-19 Warner-Lambert Company Method for the treatment of incontinence
FR2823672B1 (fr) * 2001-04-23 2004-03-12 Berkem Sa Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes
WO2005037200A2 (en) * 2003-10-09 2005-04-28 Pacific Arrow Limited Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
JP2003088335A (ja) * 2001-09-14 2003-03-25 Pharmafoods Kenkyusho:Kk 排尿機能改善用食品組成物及びそれを含有する飲食品
GB0306568D0 (en) * 2003-03-21 2003-04-30 Unilever Plc Compositions of natural products and use thereof
NZ526350A (en) * 2003-06-09 2004-10-29 A Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol
CN1867327A (zh) * 2003-09-11 2006-11-22 什诺波特有限公司 使用gaba类似物的前药治疗和/或预防尿失禁
US20070116839A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith
EP1889612A3 (en) * 2006-07-24 2008-03-19 Jan Kees Piet Bruinstroop Method for controlling micturition
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition

Also Published As

Publication number Publication date
PE20142324A1 (es) 2015-01-16
ES2423254A1 (es) 2013-09-18
CA2864426A1 (en) 2013-08-22
CR20140419A (es) 2014-11-28
WO2013121061A1 (es) 2013-08-22
IL233978A0 (en) 2014-09-30
MA37324A1 (fr) 2016-03-31
KR20140127874A (ko) 2014-11-04
US20150044308A1 (en) 2015-02-12
US9272011B2 (en) 2016-03-01
MX2014009464A (es) 2014-11-12
CN104254338B (zh) 2019-05-31
EP2815755A1 (en) 2014-12-24
PH12014501823A1 (en) 2014-11-24
MX367671B (es) 2019-08-30
JP6203761B2 (ja) 2017-09-27
EA028184B1 (ru) 2017-10-31
JP2015507002A (ja) 2015-03-05
EP2815755A4 (en) 2015-08-05
EA201491437A1 (ru) 2015-06-30
CL2014002128A1 (es) 2015-03-13
BR112014020154A8 (pt) 2017-07-11
ZA201406668B (en) 2016-05-25
AU2013220284A1 (en) 2014-09-25
ES2423254B1 (es) 2014-03-26
BR112014020154A2 (es) 2017-06-20
CN104254338A (zh) 2014-12-31

Similar Documents

Publication Publication Date Title
UY32497A (es) "2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso"
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
DOP2013000252A (es) FORMULACION PARA ANTICUERPO ANTI-a4ß7
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CO6751277A2 (es) Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes
AR080295A1 (es) Composiciones para el cuidado bucal y metodos de tratamiento
BR112014007902A2 (pt) composições farmacêuticas compreendendo 40-o-(2-hidróxi)etil-rapamicina
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
UY31922A (es) Compuestos
BR112012012862A2 (pt) composição farmacêutica compreendendo oligopeptídeos
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
CO6640216A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
CO7101247A2 (es) Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas
UY32650A (es) Medicamento para la administración oral que contiene al menos un esterógeno y/o al menos un gestágeno y al menos una cepa de bacterias probióticas
BRPI1006849B8 (pt) composição compreendendo extratos lipofílicos de zingiber officinale e echinacea angustifolia e seu uso na preparação de um medicamento para prevenção e tratamento de refluxo esofágico
CO7141408A2 (es) Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
AR089114A1 (es) PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
ECSP088588A (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada
WO2011027344A3 (en) Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders
WO2011141113A3 (de) Kombination aus vitamin k und nikotinamid
ES2446494B1 (es) Aplicación terapéutica de necrostatina-1 en esteatohepatitis